In a report released today, Sachin Jain from Bank of America Securities reiterated a Hold rating on GlaxoSmithKline, with a price target of p2,000.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sachin Jain has given his Hold rating due to a combination of factors that balance near-term execution with lingering risk. FY25 results slightly topped expectations on earnings and operating profit, yet the company’s FY26 outlook embeds constant-currency growth that is offset by a sharper-than-anticipated foreign exchange drag, leaving earnings and operating income projections roughly 3% shy of consensus and implying a modest margin step-down.
Within business segments, Specialty and Vaccines posted modest beat dynamics led by Jemperli, Benlysta, Arexvy and Shingrix, but these gains were tempered by weakness in Blenrep and GenMeds, while the upcoming launch slate (Blenrep re-entry, Depemokimab) and three major pipeline events offer upside optionality without resolving uncertainties over the HIV patent cliff and the ability to lift sales beyond flat consensus around GBP32–34 billion through 2031. Consequently, the valuation already prices in the favorable elements, and management’s reiterated medium-term sales ambition above GBP40 billion hinges on flawless pipeline execution, justifying a Hold stance.
According to TipRanks, Jain is a 3-star analyst with an average return of 3.8% and a 57.24% success rate. Jain covers the Healthcare sector, focusing on stocks such as Sanofi, Novartis AG, and Novo Nordisk.
In another report released on January 27, Citi also initiated coverage with a Hold rating on the stock with a £19.00 price target.